In the present study, we reported an improved PPV of NPC screening by a two‐step serological screening scheme, with the combination of EBNA1/IgA and VCA/IgA in the first step and anti‐EA antibodies in the second step. This evidence concerns the gene CD79A and nasopharyngeal carcinoma.